Related Experiment Video
Updated: Jun 29, 2026
09:38
Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
Published on: April 14, 2016
What is a new drug worth? An innovative model for performance-based pricing
G Dranitsaris1, K Dorward, R C Owens
1School of Medicine, University of Ioannina, Ioannina, Greece.
European Journal of Cancer Care
|September 27, 2014
Summary
This study proposes a novel performance-based pricing model for new pharmaceuticals, aiming for earlier patient access and transparent drug pricing through multi-stakeholder negotiations.
Area of Science:
- Health Economics
- Pharmaceutical Policy
- Drug Pricing Strategies
Background:
- Current pharmaceutical pricing models lack transparency and stakeholder inclusivity.
- Existing methods for new drug pricing do not adequately reflect drug performance or evolving value.
- Healthcare systems face challenges in balancing innovation, access, and affordability.
Purpose of the Study:
- To introduce a novel performance-based pricing model for new pharmaceuticals.
- To enhance transparency and stakeholder involvement in drug pricing negotiations.
- To align drug prices with demonstrated therapeutic performance and value.
Main Methods:
- Review of current pharmaceutical pricing models and historical alternatives.
- Development of a progressive, multi-stage negotiation framework for drug pricing.
- Integration of drug performance metrics into a value-based pricing construct.
Main Results:
- The proposed model facilitates earlier and wider access to innovative treatments.
- It enhances transparency in drug pricing through phased negotiation stages.
- The model allows for recognition of product performance and value changes, improving ROI predictability for developers and risk-sharing for end-users.
Conclusions:
- Performance-based drug pricing offers a more equitable and sustainable model for healthcare systems.
- This approach fosters collaboration among stakeholders, leading to better health outcomes.
- Implementing such a model can drive innovation while managing costs effectively.
Related Concept Videos
01:17Drug Nomenclature
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...